Overview | AstraZeneca at a glance We are a global, innovation-driven biopharmaceutical business Our primary focus is the discovery, development and commercialisation of prescription Financial summary medicines for six important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology and Respiratory & Inammation.
We operate in over 100 countries and our innovative medicines are used by millions of patients worldwide.
We are one of only a handful of companies to span the entire $27.97bn life-cycle of a medicine from discovery, early and late-stage development, to the global Sales down 15% at CER to $27,973 million commercialisation of primary care, specialty care-led and specialty care medicines.
Using $33,591 million in 2011 these skills and capabilities we can make a real difference to the health of a broad range of patients by delivering great medicines in disease areas where there is unmet medical need.
We want AstraZeneca to be valued as a source of great medicines and trusted as a company that delivers business success responsibly.
Our Responsible Business Plan $10.4bn provides the framework for ensuring that we operate with integrity and high ethical Core operating profit down 18% at CER standards across all our activities.
to $10,430 million $13,167 million in 2011 $8.1bn Reported operating profit down 34% at CER to $8,148 million $12,795 million $10,655m in 2011 Regional sales US -21% $6.41 Core EPS for the full year decreased by 9% at CER to $6.41 $7.28 in 2011 14, 400 employees in the Americas 27.9% $4.99 Reported EPS for the full year decreased by 29% at CER to $4.99 $7.33 in 2011 30,200 $5.9bn Sales and Marketing employees: numbers Net cash shareholder distributions in Established Markets, such as the US, decreased by 37% to $5,871 million have fallen, whereas the numbers in including net share repurchases Emerging Markets have increased and of $2,206 million $9,370 million net now represent 53% of the total cash shareholder distributions including $5,606 million net share repurchases in 2011 Our medicines Our 10 leading medicines by sales value are: Cardiovascular Gastrointestinal Infection Atacand Seloken Toprol-XL Nexium Synagis Crestor for hypertension for hypertension, heart for acid-reux for RSV, a respiratory for managing and heart failure failure and angina infection in infants cholesterol levels 2010: $1,483m 2010: $1,210m 2010: $4,969m 2010: $1,038m 2010: $5,691m 2011: $1,450m 2011: $986m 2011: $4,429m 2011: $975m 2011: $6,622m 2012 2012 2012 20 201 12 2 2012 $1,009m $6,253m $918m $3 $3, 9 944 44m m $1,038m -27% -4% -4% - -1 10 0% % 6% 2 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information $6,486m 51,700 Regional sales Western Europe -19% employees worldwide 23,600 employees in EMEA 45.6% $5,080m Regional sales Established ROW -14% $5,752m Regional sales Emerging Markets 4% 13, 700 employees in Asia Pacic 26.5% 9,800 employees work in our R&D organisation and we have 10 principal R&D centres in six countries 10, 300 employees work at our 22 Supply and Manufacturing sites in 16 countries All gures are approximate.
Neuroscience Oncology Respiratory & Inammation Seroquel IR Seroquel XR Zoladex Pulmicort Symbicort for schizophrenia for schizophrenia, bipolar for prostate for asthma and chronic for asthma and chronic and bipolar disorder disorder and major and breast cancer obstructive pulmonary obstructive pulmonary depressive disorder disease disease 2010: $4,148m 2010: $1,154m 2010: $1,115m 2010: $872m 2010: $2,746m 2011: $4,338m 2011: $1,490m 2011: $1,179m 2011: $892m 2011: $3,148m 2012 2012 2012 2012 2012 $3,194m $1,294m $1,509m $1,093m $866m -70% 4% -5% -1% 5% AstraZeneca Annual Report and Form 20-F Information 2012 3 Overview | AstraZeneca at a glance Financial overview Sales Core pre-R&D operating profit Core operating profit $m -15% $m -16% $m -18% 12 27,973 12 10,430 12 14,882 11 33,591 11 13,167 11 18,200 10 33,269 10 13,603 10 17,822 Reported operating profit Net cash ow from Reported pre-R&D $m -34% operating activities $m operating profit $m -25% 12 8,148 12 6,948 12 13,391 11 12,795 11 7,821 11 18,318 10 11,494 10 10,680 10 16,812 Our year in brief February AstraZeneca March AstraZeneca and April Entered into June David Brennan announces an accelerated Targacept decide not to pursue agreement to acquire retires as CEO R&D transformation regulatory ling on TC-5214 due Ardea and its Phase III Louis Schweitzer retires programme and the end to inconclusive Phase III results development product as Chairman of the Board of R&D activity at sites in candidate, lesinurad, as a As anticipated, the Seroquel IR and Leif Johansson starts Sweden Sdertlje and potential treatment for the patent in the US expired, a number as the new Chairman Canada Montreal chronic management of of generic products entered the hyperuricaemia in patients market and our sales declined with gout 2012 F M A M J J J March AstraZeneca receives approval April AstraZeneca agrees June AstraZeneca from the FDA for FluMist Quadrivalent for enhances its presence with Amgen to jointly the prevention of inuenza.
This marked develop and commercialise in Asia with the opening the first four-strain inuenza vaccine, and of the Zhangjiang Park five monoclonal antibodies the only intra-nasal four-strain vaccine, from Amgens clinical Regional Hub Headquarters approved by the FDA in Shanghai inammation portfolio Operational overview Pipeline Deliver the business 84 88 11% 15% $4.5bn pipeline projects countries reduction in R&D reduction in revenue loss of exclusivity expense reduction 84 pipeline projects Brilinta Brilique has Core R&D expense for Revenue fell by 21% in Some $4.5 billion of including 71 in clinical been approved in 88 the full year was down the US: 19% in Western revenue decline was development, of which countries, launched 11%, despite absorbing Europe: and 14% in related to loss of 11 are in Phase III or in 82 countries and higher costs from Established Rest of exclusivity on several under regulatory review: remains under review spending on in-licensed, World.
Revenue rose by brands in the portfolio.
acquired or partnered 4% in Emerging Markets Seroquel IR declined theyear Global sales of projects, as these were by more than $3 billion: $89 million in 2012 more than offset by regional losses of restructuring benets exclusivity for Atacand, and lower intangible Nexium and Crestor impairments than had a further negative in 2011 impact of more than $1 billion 4 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information Shareholder distributions Distributions to shareholders $m Core earnings per Ordinary Share $ -9% 2012 2011 2010 Dividends 3,665 3,764 3,361 12 6.41 1 2 3 4 Share repurchases 2,635 6,015 2,604 11 7.28 Total 6,300 9,779 5,965 10 6.71 Dividend for 2012 $ Pence SEK Payment date Reported earnings per First interim dividend 0.90 58.1 6.26 10 September 2012 Ordinary Share $ -29% Second interim dividend 1.90 120.5 12.08 18 March 2013 12 4.99 Total 2.80 178.6 18.34 11 7.33 1 The share repurchase programme was suspended effective 1 October 2012.
2 Share repurchases in 2012, net of proceeds from the issue of share capital equal 10 5.60 to $429 million, were $2,206 million.
3 Share repurchases in 2011, net of proceeds from the issue of share capital equal to $409 million, were $5,606 million.
4 Share repurchases in 2010, net of proceeds from the issue of share capital equal to $494 million, were $2,110 million.
August Expansion of BMS October Pascal Soriot November Forxiga approved diabetes alliance through starts as CEO in Europe for the treatment inclusion of the Amylin product of Type 2 diabetes Suspension of share portfolio repurchase programme EU gives marketing authorisation for Zinforo A S O 2012 N D 2013 J September AstraZeneca October Collaboration January 2013 Changes with Ironwood in China to the Senior Executive Team ranks in the top 7% in the sector in the Dow Jones Sustainability to co-develop and coannounced commercialise linaclotide World and European Indexes, with a score of 83% Business shape People $600m $1.85bn 12% 81% 5,500 revenue growth in benefits reduction in SG&A score reduction in employees Symbicort, Faslodex, By the end of 2012, Expenditures in Core Our employee Net reduction of some Onglyza, Iressa, Brilinta annual benets of SG&A were 12% lower engagement score 5,500 employees Brilique and Seroquel $1.85 billion had than 2011, a result of in our annual FOCUS since 2011 included XR combined to deliver been realised from restructuring benets survey among recruitment of $600 million of revenue the phases of our and spending discipline all employees approximately 5,700 growth restructuring partially offset by decreased by three employees to drive programme announced inclusion of amortisation percentage points our expansion in in 2010 and 2012 expense related to the compared with 2011 Emerging Markets, expansion of the build new capabilities diabetes alliance with and replace leavers BMS and increased promotional cost in Emerging Markets AstraZeneca Annual Report and Form 20-F Information 2012 5
